VIVA BIOTECH (01873.HK) announces a profit warning. Compared to a net loss attributable to shareholders of 0.116 billion RMB in the previous year, it is expected that the net profit attributable to shareholders for the 2024 fiscal year will be between 0.15 billion and 0.18 billion RMB. The turnaround to profit is mainly due to the recovery of growth in the contract research organization Business in the second half of the year, improved operational efficiency leading to an increase in operating profit margin, and the confirmation of investment income from milestone payments received during the year.